• 1. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Recent Advances in the Study of N-Methyl(phenyl)-N-(2-piperidinylmethyl)-methanamine Dihydrochloride (CAS: 1220019-08-8)

N-Methyl(phenyl)-N-(2-piperidinylmethyl)-methanamine dihydrochloride (CAS: 1220019-08-8) is a compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential applications in drug development, particularly in the context of neurological disorders and receptor modulation. This research brief synthesizes the latest findings, methodologies, and implications associated with this compound, providing a comprehensive overview for professionals in the field.

The compound has garnered attention due to its structural similarity to known pharmacophores that interact with central nervous system (CNS) receptors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its affinity for sigma-1 and sigma-2 receptors, which are implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's. The study utilized radioligand binding assays and molecular docking simulations to elucidate the binding mechanisms, revealing a promising scaffold for further optimization.

Another key area of research focuses on the compound's pharmacokinetic properties. A preclinical investigation conducted by researchers at the University of California, San Francisco, evaluated its bioavailability and metabolic stability in rodent models. The results, published in Drug Metabolism and Disposition, indicated moderate oral bioavailability and a half-life suitable for potential therapeutic applications. However, the study also highlighted the need for structural modifications to mitigate first-pass metabolism.

In addition to its CNS applications, N-Methyl(phenyl)-N-(2-piperidinylmethyl)-methanamine dihydrochloride has been investigated for its role in cancer therapy. A 2024 study in Oncotarget explored its cytotoxic effects on glioblastoma cell lines, demonstrating selective apoptosis induction via the mitochondrial pathway. The researchers employed flow cytometry and Western blotting to validate these findings, suggesting a potential dual mechanism of action involving receptor modulation and direct cellular toxicity.

Despite these promising results, challenges remain in translating this compound into clinical use. Issues such as off-target effects, dose-limiting toxicity, and synthetic scalability must be addressed. Collaborative efforts between academic institutions and pharmaceutical companies are underway to optimize the compound's properties and advance it through preclinical development. Future research directions may include the development of prodrug formulations or targeted delivery systems to enhance efficacy and reduce adverse effects.

In conclusion, N-Methyl(phenyl)-N-(2-piperidinylmethyl)-methanamine dihydrochloride represents a versatile scaffold with potential applications in neurology and oncology. Continued research and optimization are essential to unlock its full therapeutic potential and address current limitations. This brief underscores the importance of interdisciplinary collaboration and innovative methodologies in advancing chemical biology and drug discovery.

• 168466-84-0((R)-3-Amino-1-benzylpiperidine)
• 170701-98-1(2-Aminomethyl-1-benzyl-piperidine)
• 168466-85-1((S)-1-Benzyl-3-aminopiperidine)
• 60407-35-4(1-Benzylpiperidin-3-amine)
• 60717-45-5(1-benzyl-N-methylpiperidin-3-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)